Login to Your Account

Changing Exclusivity Could Have Ramifications for FDA

By Mari Serebrov

Wednesday, September 21, 2011
The president's proposal to shorten the exclusivity period for biologics in fiscal 2012 as a debt-busting move could end up costing the government money by opening the floodgates to biosimilars long before the FDA is ready.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription